VSL# 3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases

TM Chapman, GL Plosker, DP Figgitt - Drugs, 2006 - Springer
VSL#3 are derived from in vitro studies and animal models, and further study is warranted into
the immune responses associated with VSL… response following oral treatment with VSL#3. …

[HTML][HTML] Probiotic mixture VSL# 3: An overview of basic and clinical studies in chronic diseases

FS Cheng, D Pan, B Chang, M Jiang… - World journal of clinical …, 2020 - ncbi.nlm.nih.gov
… of VSL#3 in chronic diseases of animals and humans (including children). We found that
VSL#… This review seeks to provide an overview of the role of VSL#3 in various kinds of diseases …

A randomized controlled trial of a probiotic, VSL# 3, on gut transit and symptoms in diarrhoea‐predominant irritable bowel syndrome

HJ Kim, M Camilleri, S McKinzie… - Alimentary …, 2003 - Wiley Online Library
Aim : To investigate the effects of a probiotic formulation, VSL#3, on gastrointestinal transit
and symptoms of patients with Rome II irritable bowel syndrome with predominant diarrhoea. …

Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL# 3 for active ulcerative colitis: A systematic review and meta-analysis

X Dang, M Xu, D Liu, D Zhou, W Yang - PloS one, 2020 - journals.plos.org
VSL#3 seems more safer than fecal microbiota transplantation, because serious adverse
events were not reported in the VSL… and that of mixed probiotics VSL#3. However, the use of …

Once daily high dose probiotic therapy (VSL# 3) for maintaining remission in recurrent or refractory pouchitis

T Mimura, F Rizzello, U Helwig, G Poggioli, S Schreiber… - Gut, 2004 - gut.bmj.com
… The probiotic preparation used in this study was VSL#3 (VSL pharmaceuticals Inc., Fort
Lauderdale, USA). VSL#3 3 g sachets contain 300 billion bacteria/g, comprising four strains of …

Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL# 3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized …

A Tursi, G Brandimarte, A Papa, A Giglio… - Official journal of the …, 2010 - journals.lww.com
… conducted with VSL#3, a product that has proven to be effective for the treatment and
prevention of pouchitis ( 3 ). The aim of this investigation was to assess whether, by adding VSL#3 …

The probiotic preparation, VSL# 3 induces remission in patients with mild-to-moderately active ulcerative colitis

A Sood, V Midha, GK Makharia, V Ahuja… - Clinical …, 2009 - Elsevier
VSL#3 has been reported to achieve remission/response in children with mild to moderate
UC.24, 25 Although there is growing data on the efficacy of VSL… and safety of VSL#3 in mild-to…

Beneficial effects of a probiotic VSL# 3 on parameters of liver dysfunction in chronic liver diseases

C Loguercio, A Federico, C Tuccillo… - Journal of clinical …, 2005 - journals.lww.com
Objectives: To evaluate whether chronic therapy with probiotics affects plasma levels of
cytokines and oxidative/nitrosative stress parameters, as well as liver damage, in patients with …

The probiotic VSL# 3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease

RN Fedorak, BG Feagan, N Hotte, D Leddin… - Clinical …, 2015 - Elsevier
Background & Aims Probiotic formulations of single species of bacteria have not been effective
in preventing the recurrence of Crohn’s disease after surgery. We investigated the ability …

Probiotic preparation VSL# 3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study

HQ Huynh, J debruyn, L Guan, H Diaz… - Inflammatory bowel …, 2009 - academic.oup.com
… The primary objective of this study was to monitor the clinical efficacy of VSL#3 therapy in …
to investigate the safety of VSL#3 in children with UC. Prior to and post-VSL#3 treatment serum …